Catriona Yale - Dec 8, 2021 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Development Officer
Signature
/s/ Jonathan Young, Attorney-in-fact
Stock symbol
AKRO
Transactions as of
Dec 8, 2021
Transactions value $
$0
Form type
4
Date filed
12/10/2021, 04:08 PM
Previous filing
Oct 18, 2021
Next filing
Sep 13, 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Award $0 +87.2K $0.00 87.2K Dec 8, 2021 Common Stock 87.2K $21.10 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable in 48 equal monthly installments commencing on December 8, 2021.